Satellos Bioscience (MSLE) Operating Expenses (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Operating Expenses of $10.0 million for Q1 2026, up 55.01% year-over-year from $6.5 million in Q1 2025, and up 55.01% quarter-over-quarter from $6.5 million in Q1 2025.
Satellos Bioscience (MSLE) Operating Expenses (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Operating Expenses for 2 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 55.01% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $16.5 million (changed N/A YoY), while the FY2025 annual figure was $26.5 million, up 32.92% from the prior year.
- Operating Expenses rose to $10.0 million in Q1 2026 per MSLE's latest filing, from $6.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $10.0 million in Q1 2026 and bottomed at $6.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | 12.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.04 Mn |
| Mar 31, 2025 | 6.48 Mn |